Peptides DB
Research-centric peptide and protocol reference hub

MGF (Mechano Growth Factor) record · updated 6h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 28 studiesJump to the evidenceCompare
What is MGF (Mechano Growth Factor) used for?

MGF (Mechano Growth Factor) is a locally expressed IGF-1 splice variant studied in preclinical models for muscle satellite cell activation, repair, and recovery from tissue injury.

How it works: Activates satellite cell proliferation and differentiation via PI3K/Akt and mTOR pathways

Primarily researched for · Muscle & body comp

Development stage

where MGF (Mechano Growth Factor) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 93 registered trials. It describes the research record, not a recommendation.

Identity
NameMGF (Mechano Growth Factor)
Chain length—
Molecular weight81.3 Da
FormulaF3Mg-
Structure typeSmall molecule
ClassMuscle
Research levelPreclinical
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 447728. No verified residue count for this compound.

Pharmacology
MechanismActivates satellite cell proliferation and differentiation via PI3K/Akt and mTOR pathways
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.70
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 21, 2026. How this works →
Research stats
Total studies28
Human / animal / cellular11 / 7 / 2
Highest trial phasePhase 4
Years covered2015–2026
Latest study6h ago
Publication history
20152026
Research funding
10 NIH projects · $3.2M awarded · through FY2013
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

28 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
The NUS-Lancet PRIME Commission: transforming pandemic readiness for equity.
TakeawayNot reported in abstract.
—2026Title only0.10
Enhancement of growth performance, muscle nutrient composition, and nutritional value in rainbow trout (<i>Oncorhynchus mykiss</i>) by guanidinoacetic acid-enriched diets.
Finding72.806 EAAI in the G6 group, P < 0.001.
Animal2026Full text read0.80
A new species of Hepatozoon Miller, 1908 (Apicomplexa: Hepatozoidae) parasitizing Philodryas nattereri (Squamata: Dipsadidae) from the Caatinga, Brazil.
Finding100% of specimens were parasitized.
Animal2026Full text read0.80
Cell and gene therapies in managed care: US payer insights on coverage and financial risk.
FindingNot reported in abstract.
review2026Full text read0.80
Assessing digital health curriculum needs: a mixed-methods study of student and faculty perspectives in a Singapore medical school.
Finding131 responses from 848 eligible participants.
review2026Full text read0.80
Lymphocytic Esophagitis Mimicking Eosinophilic Esophagitis and Esophageal Candidiasis: A Case Report.
FindingNot reported in abstract.
Human2023Full text read0.80
Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia.
Finding1.74 cm per year increase in annualized height velocity vs placebo at week 52, 95% CI 1.31 to 2.17, P<0.001
Human2026Full text read0.90
Lactate suppresses STING activation to promote tumor immune evasion.
TakeawayNot reported in abstract.
—2026Title only0.10
Microbiome-based therapeutics for &lt;i&gt;Clostridioides difficile&lt;/i&gt; infection: additive, subtractive, and modulatory strategies in modern clinical practice.
TakeawayMicrobiome-based therapies for CDI represent a promising shift towards ecological treatment strategies, but further clinical validation is needed.
review2026Full text read0.80
Efficient brain delivery and sustained retention of antibodies via dual targeting of blood-brain barrier and intra-brain proteins.
FindingSustained brain concentrations of anti-MOG/TfR antibody for 4 months.
Animal2026Full text read0.80
Mechanoregulating HA-integrated anisotropic fibrous vessel promote AKT-sensitive and YAP-associated endothelial responses and improve regional lymphatic drainage in lymphedema.
FindingReduced ankle swelling in a rat lymphedema model.
Animal2026Full text read0.80
Correlation of the estimated glucose disposal rate with self-reported endometrial cancer: a cross-sectional study from NHANES 1999-2018.
FindingOdds ratio for eGDR inversely associated with self-reported EC was 0.906 (95% CI: 0.826-0.991, P = 0.0328)
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching MGF (Mechano Growth Factor) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much MGF (Mechano Growth Factor) is discussed should be drawn from it.

Articles mentioning MGF (Mechano Growth Factor)